Medicare GLP-1 prior authorization in 2026: bridge eligibility and approval steps

Medicare coverage for GLP-1 medications changed in 2026, but approval still depends on why the drug is prescribed, the patient’s coverage, and the clinical information submitted with the request. For provider offices, the most important first step is deciding whether the prescription belongs with the patient’s regular Part D plan or the temporary Medicare GLP-1 Bridge.

This guide explains the Medicare GLP-1 prior authorization process in practical terms, including who may qualify, which products are included, what the provider must document, and where authorization requests commonly slow down.

What changed for Medicare GLP-1 coverage in 2026?

CMS launched the Medicare GLP-1 Bridge demonstration on July 1, 2026. The program operates outside the standard Medicare Part D coverage and payment flow. A central processor handles prior authorization, pharmacy claim adjudication, and payment for eligible prescriptions.

The Bridge is designed for eligible beneficiaries who use an included GLP-1 drug to reduce excess body weight or maintain weight reduction. It is not the correct route when the drug is prescribed for an indication already covered under the patient’s Part D plan.

Who may qualify for the Medicare GLP-1 Bridge?

The patient must be at least 18 years old, have an eligible type of Medicare drug coverage, and use the GLP-1 drug with ongoing lifestyle modification that includes structured nutrition and physical activity. The patient must also have met one of the following clinical pathways when GLP-1 therapy began.

BMI of 35 or higher

No additional qualifying condition is required under this pathway.

BMI of 30 or higher

The patient must also have heart failure with preserved ejection fraction, uncontrolled hypertension, or chronic kidney disease at stage 3a or higher.

BMI of 27 or higher

The patient must also have prediabetes, a previous heart attack, a previous stroke, or symptomatic peripheral artery disease.

The starting BMI matters. CMS bases eligibility on the patient’s BMI when GLP-1 therapy began, not only the BMI recorded on the date of the authorization request. A patient who has already lost weight may still qualify when the medical record supports the BMI at treatment initiation.

Provider offices should confirm the patient’s plan type before starting the request. The Medicare weight loss drug coverage page lists eligible coverage types and provides a patient-facing eligibility checker.

Which GLP-1 drugs are included?

As of August 3, 2026, the Medicare GLP-1 Bridge includes the following products when they are prescribed for weight reduction or maintenance of weight reduction.

Drug	Included formulation	Important detail
Foundayo	Tablet formulations	Included under the Bridge product list.
Wegovy	Injection and tablet formulations	Included formulations may be subject to the listed National Drug Codes.
Zepbound	KwikPen only	Single-dose pens and single-dose vials are not included.

CMS may update the product and National Drug Code list during the demonstration. Check the current CMS information for providers before submitting an authorization.

How does Medicare GLP-1 prior authorization work?

1. The provider sends the prescription to the pharmacy. The prescription should identify an eligible drug and a use covered by the Bridge.
2. The pharmacy submits the claim to the Medicare GLP-1 Bridge. A Part D denial is not required before the pharmacy routes an eligible claim to the Bridge.
3. The pharmacy sends the prior authorization request to the prescriber. After the claim is processed and prior authorization is required, the pharmacy generally transmits the request electronically or by fax within 24 to 72 hours.
4. The provider completes the clinical attestation. The request should support the patient’s BMI at therapy initiation, any qualifying diagnosis, the weight-management indication, and the ongoing nutrition and physical activity plan.
5. The central processor issues a determination. CMS states that the approval or denial is sent to the patient and prescriber within 72 hours after submission.

Once the medication is approved, patients typically will not need another authorization for refills or dose adjustments through December 31, 2027. However, if they change to a different covered GLP-1 medication, the provider must submit a new prior authorization request.

What should the provider document?

CMS recommends including diagnosis information or an annotation that helps the pharmacy route the prescription, although that information is not required for the Bridge processor to accept the claim. A consistent front-end workflow can reduce missing documentation and handoff errors. RCMGen’s clinic and physician group revenue cycle management model connects eligibility, prior authorization, billing, and denial follow-up instead of treating each step as a separate queue.

When should the request go to the Part D plan instead?

The Medicare GLP-1 Bridge is for eligible weight-management prescriptions. The request should generally go to the patient’s Part D plan when the GLP-1 is prescribed for a Part D-covered indication, including:

• Type 2 diabetes.
• Moderate-to-severe obstructive sleep apnea.
• Noncirrhotic metabolic dysfunction-associated steatohepatitis, or MASH, with qualifying fibrosis.
• Reduction of major adverse cardiovascular event risk in a patient with established cardiovascular disease.

The Part D plan can apply its own formulary, step therapy, and prior authorization rules. Confirming the treatment indication before submission helps prevent the request from moving through the wrong coverage route.

Common reasons a Medicare GLP-1 authorization is delayed

• The pharmacy has not submitted the claim to the Bridge before the provider sends the authorization form.
• The request includes the patient’s current BMI but does not document the BMI at treatment initiation.
• The prescription is routed to the Bridge even though the indication belongs under Part D.
• The prescription uses a formulation that is not included in the Bridge product list.
• The provider does not complete the lifestyle-modification attestation.
• The patient changes GLP-1 drugs without a new authorization request.
• The clinical diagnosis does not clearly support the selected BMI eligibility pathway.

Prior authorization work becomes easier to manage when the team tracks the prescription, pharmacy response, documentation request, submission date, and determination in one workflow. RCMGen’s prior authorization services for hospitals, clinics, and physician groups support requirement screening, clinical document assembly, submission tracking, and payer follow-up.

What happens if the Bridge request is denied?

The Medicare GLP-1 Bridge does not have a separate appeal process. If the original request contained incorrect information, or the provider has updated or additional clinical information, the provider may correct the form and resubmit the prior authorization request. That makes a complete first submission especially important.

Medicare GLP-1 prior authorization FAQs